Last updated on October 2018

Preserve-Transplant Study

Brief description of study

The aim of this study is to test if alkali treatment will preserve kidney graft function and diminish the progression of chronic kidney disease in renal transplant patients. Additionally the underlying mechanisms of nephrotoxicity of metabolic acidosis will be investigated in this cohort.

This study is a multi-center, prospective, randomized, single-blind (patient), placebo-controlled interventional trial to test the superiority of alkali treatment in comparison to placebo on preservation of kidney function in 300 kidney transplant recipients. The duration of the study will be 2 years for the individual participant. The patients will be randomized into 2 arms: intervention arm (sodium hydrogen carbonate, product: Nephrotrans) and placebo arm (placebo comparator).

Several studies in CKD (chronic kidney disease) patients have shown that alkali therapy slows progression of CKD.

Clinical Study Identifier: NCT03102996

Contact Investigators or Research Sites near you

Start Over

Spyridon Arampatzis, PD Dr. med.

Inselspital Bern, Department of Nephrology and Hypertension
Bern, Switzerland
  Connect »

Karine Hadaya, PD Dr. med.

HUG - N phrologie
Geneva, Switzerland
  Connect »

Nilufar Mohebbi, PD Dr. med.

University Hospital Zurich, Division of Nephrology
Zurich, Switzerland
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.